News
Lower Risk of CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
Your search for Warfarin returned 199 results
Features, News
Antiplatelet Therapy in COPD May Reduce All-Cause Mortality, Improve QoL
Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.
News
Osteoporotic Fracture Risk Lower for DOAC Than Warfarin in A-Fib
No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants
News
Bleeding Risk Assessed With Concomitant Direct Oral Anticoagulants and Verapamil or Diltiazem
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
News
Potential Links ID’d for Marijuana Use, Cardiovascular Risks
Key classes of cardiovascular medications are affected by marijuana, including statins, β-blockers.
News
Time of Day for Taking Warfarin Does Not Matter
Morning or evening administration makes no difference on time outside target INR range.
News
Cannabis May Alter the Effects of Anticoagulants, Antiplatelets
A recent review published in The Journal of Clinical Pharmacology summarizes the current literature evaluating the potential risks associated with concomitant use of cannabis and antiplatelet agents or anticoagulants.
News
Risk for Death Cuts Benefit of Oral Anticoagulants for A-Fib
Findings seen among older patients with incident atrial fibrillation receiving warfarin or apixaban
News
Low-Intensity Warfarin Not Noninferior in Hip, Knee Surgery
Noninferiority not found compared with standard-intensity prophylaxis with hip or knee arthroplasty
Features, News
Consider CBD-Drug Interaction Potential: An Expert Interview
To shed light on this complex subject, MPR interviewed Joshua D Brown, PharmD, PhD, Assistant Professor, Pharmaceutical Outcomes & Policy.
